Clinical Trial Update: Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment [Phase 2]

View source ↗

Summary

A Phase 2 rollover protocol study of nilotinib for patients with Gastrointestinal Stromal Tumors has completed, and the trial results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED | Results posted: 2024-08-19